Ascentage Pharma Successfully Passes All AGM Resolutions

Ascentage Pharma Group International ( (HK:6855) ) has issued an announcement.

Ascentage Pharma Group International announced the successful passage of all resolutions at its Annual General Meeting held on May 19, 2025. Key resolutions included the re-election of board members, authorization of director remuneration, reappointment of Ernst & Young as auditors, and granting mandates for share issuance and repurchase. These decisions reflect the company’s strategic direction and governance stability, which may positively impact investor confidence and support its ongoing growth and development initiatives.

The most recent analyst rating on (HK:6855) stock is a Buy with a HK$40.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.

More about Ascentage Pharma Group International

Ascentage Pharma Group International is a biopharmaceutical company incorporated in the Cayman Islands, focusing on developing therapies for cancer, chronic hepatitis B, and age-related diseases. The company is listed on the Hong Kong Stock Exchange and is known for its innovative approach in targeting apoptosis pathways to treat these conditions.

Average Trading Volume: 4,273,121

Technical Sentiment Signal: Buy

Current Market Cap: HK$15.49B

For a thorough assessment of 6855 stock, go to TipRanks’ Stock Analysis page.